CanSino Biologics Valuation

Is CJH undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CJH when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CJH (€3.14) is trading below our estimate of fair value (€32.29)

Significantly Below Fair Value: CJH is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CJH?

Key metric: As CJH is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CJH. This is calculated by dividing CJH's market cap by their current revenue.
What is CJH's PS Ratio?
PS Ratio8.3x
SalesCN¥748.53m
Market CapCN¥10.43b

Price to Sales Ratio vs Peers

How does CJH's PS Ratio compare to its peers?

The above table shows the PS ratio for CJH vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average9.4x
BIO3 Biotest
1.5x3.6%€1.4b
MOR MorphoSys
10.2xn/a€2.6b
FYB Formycon
13.6x33.4%€827.2m
HPHA Heidelberg Pharma
12.3x16.6%€103.9m
CJH CanSino Biologics
8.3x33.3%€11.2b

Price-To-Sales vs Peers: CJH is good value based on its Price-To-Sales Ratio (8.3x) compared to the peer average (9.4x).


Price to Sales Ratio vs Industry

How does CJH's PS Ratio compare vs other companies in the DE Biotechs Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
CNW co.don
0.7xn/aUS$6.97m
V9Z Aceragen
0.4xn/aUS$3.12m
PA8 Paion
0.2x30.2%US$2.78m
V9Z Aceragen
0.3x-161.8%US$2.18m
CJH 8.3xIndustry Avg. 7.9xNo. of Companies6PS0612182430+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: CJH is expensive based on its Price-To-Sales Ratio (8.3x) compared to the European Biotechs industry average (7.9x).


Price to Sales Ratio vs Fair Ratio

What is CJH's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CJH PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio8.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CJH's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CJH forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€3.55
0%
18.6%€4.45€2.67n/a5
Nov ’25€3.14
€3.55
+13.1%
18.6%€4.45€2.67n/a5
Oct ’25n/a
€3.13
0%
22.5%€4.41€2.44n/a5
Sep ’25n/a
€3.14
0%
23.3%€4.49€2.44n/a5
Aug ’25n/a
€3.30
0%
21.6%€4.52€2.56n/a5
Jul ’25n/a
€3.30
0%
21.6%€4.52€2.56n/a5
Jun ’25€2.48
€3.27
+31.7%
21.8%€4.48€2.51n/a5
May ’25n/a
€3.10
0%
31.1%€4.89€2.18n/a5
Apr ’25n/a
€3.11
0%
31.3%€4.94€2.20n/a5
Mar ’25€2.15
€4.10
+90.8%
14.1%€4.93€3.41n/a5
Feb ’25n/a
€4.10
0%
14.1%€4.93€3.41n/a5
Jan ’25€2.51
€8.98
+257.9%
80.6%€23.17€4.02n/a5
Dec ’24n/a
€10.46
0%
75.7%€23.94€4.56n/a4
Nov ’24n/a
€12.46
0%
66.4%€24.02€5.07€3.143
Oct ’24€3.02
€11.51
+281.3%
64.2%€24.02€5.07n/a4
Sep ’24€2.81
€10.34
+268.1%
67.0%€23.78€4.14n/a5
Aug ’24n/a
€11.60
0%
51.2%€21.50€6.84n/a4
Jul ’24n/a
€12.63
0%
44.5%€22.05€7.29n/a4
Jun ’24€3.43
€13.02
+279.9%
40.4%€22.88€7.56€2.485
May ’24n/a
€13.02
0%
40.4%€22.88€7.56n/a5
Apr ’24€5.17
€14.38
+178.3%
38.8%€23.11€7.63n/a6
Mar ’24€7.35
€15.47
+110.4%
34.1%€23.60€9.17€2.156
Feb ’24€8.04
€15.82
+96.9%
35.2%€24.94€9.21n/a6
Jan ’24€8.63
€15.76
+82.8%
34.7%€24.75€9.14€2.516
Dec ’23n/a
€15.76
0%
34.7%€24.75€9.14n/a6
Nov ’23€10.94
€14.44
+32.0%
40.2%€25.23€9.32n/a5

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies